Oncology Archives | Page 3 of 5 | Report Store

Type 1 Diabetes KOL Interview – US, Midwest

This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

January 8, 2020

Find out more

Market Spotlight: Biliary Tract Cancer

$1,318.00

This Market Spotlight report covers the Biliary Tract Cancer market, comprising key pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

December 31, 2019

Find out more

Triple-Negative Breast Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 31, 2019

Find out more

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…

October 18, 2019

Find out more

Hepatocellular carcinoma (HCC) Disease Coverage Forecast and Market Analysis to 2038

Malignant tumors of the liver are primarily adenocarcinomas, with two major cell types: hepatocellular carcinoma (ie hepatocellular cancer), and cholangiocarcinoma.

September 9, 2019

Find out more

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to its large population size.

June 1, 2019

Find out more

Bladder Cancer KOL Interview – US

$599.00

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

May 31, 2019

Find out more

Renal cell cancer (RCC) disease forecast and market analysis to 2038

Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms’ tumor (nephroblastoma).

March 6, 2019

Find out more

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow.

March 5, 2019

Find out more

Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a disease characterized by an accumulation of mature malignant B lymphocytes in the peripheral blood, bone marrow, and lymph nodes.

January 31, 2019

Find out more

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of all NHL cases.

January 30, 2019

Find out more

2018 Biomedtracker Datamonitor Healthcare Post-ASH Report

$599.00

The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.

January 3, 2019

Find out more

Breast Cancer Diagnostic and Treatment Devices

$4,750.00

This analysis includes a discussion of competitors, markets (current and future), products, and opportunities in the global market for breast cancer diagnostics.

November 28, 2018

Find out more

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

$3,000.00

This market analysis covers price-volume and expenditure ceilings are frequently used across Europe, payers are concerned about the budget impact of immunotherapies, price reductions are frequently required following label expansions into new populations, immunotherapy drugs present an opportunity for contracting, but payers await more competition and combination therapies pose challenges for payers as many markets do not have a clear path for HTA and price negotiation.

November 28, 2018

Find out more

HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

$2,995.00

Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence

October 16, 2018

Find out more